The Vanguard Group 13D and 13G filings for Verve Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 5:52 pm Unchanged | 2024-09-30 | 13G | Verve Therapeutics, Inc. VERV | The Vanguard Group | 4,005,161 4.730% | 0 (Unchanged) | Filing |
| 2024-11-04 1:52 pm Sale | 2024-09-30 | 13G | Verve Therapeutics, Inc. VERV | The Vanguard Group | 4,005,161 4.730% | -1,466,769 (-26.81%) | Filing |
| 2024-02-13 5:17 pm Purchase | 2023-12-29 | 13G | Verve Therapeutics, Inc. VERV | The Vanguard Group | 5,471,930 6.810% | 1,659,906 (+43.54%) | Filing |
| 2023-02-09 11:35 am Purchase | 2022-12-30 | 13G | Verve Therapeutics, Inc. VERV | The Vanguard Group | 3,812,024 6.190% | 3,812,024 (New Position) | Filing |